NT_1170x120_1-11-18

anaphylaxis

Walgreens and kaléo team to address epinephrine auto-injector supply issues

Walgreens and kaléo team to address epinephrine auto-injector supply issues

DEERFIELD, Ill. and RICHMOND, Va. — Walgreens and kaléo, a privately-held pharmaceutical company, are working together to improve access to epinephrine auto-injectors by making kaléo’s AUVI-Q 0.15 mg and 0.3 mg available through Walgreens locations nationwide. This comes in an effort to help thousands of Americans with their epinephrine needs during the back to school

Kaleo set to bring back Auvi-Q epinephrine injector

Kaleo set to bring back Auvi-Q epinephrine injector

RICHMOND, Va. — Pharmaceutical company Kaleo plans to reintroduce the Auvi-Q epinephrine auto-injector to the U.S. market in the first half of 2017. For emergency use in treating life-threatening allergic reactions such as anaphylaxis, Auvi-Q is expected to provide an option to the EpiPen from Mylan Inc., which has been lambasted by government officials, the

Impax highlights its generic epinephrine auto-injector

Impax highlights its generic epinephrine auto-injector

HAYWARD, Calif. — Impax Laboratories Inc. is spotlighting its generic epinephrine auto-injector amid a public outcry over the cost of emergency medication for anaphylaxis, a potentially life-threatening allergic reaction. In what Impax called an update, the company said it’s providing additional information to patients, doctors and customers about its epinephrine injection auto-injector in 0.15-mg and

Mylan set to launch generic EpiPen

Mylan set to launch generic EpiPen

PITTSBURGH — In what chief executive officer Heather Bresch called “an extraordinary commercial response,” Mylan N.V. plans to release a generic version of its EpiPen epinephrine auto-injector for anaphylaxis, answering public demands to lower the cost of the potentially life-saving product. Mylan said Monday that its U.S. subsidiary expects to roll out the generic EpiPen

Senators question pricing of Mylan’s EpiPen

Senators question pricing of Mylan’s EpiPen

NEW YORK — Senate leaders have voiced concerns about a price surge for Mylan Inc.’s EpiPen, an epinephrine auto-injector for treating anaphylaxis, or potentially life-threatening allergic reactions. Sen. Chuck Grassley (R, Iowa), chairman of the Senate Judiciary Committee, and Sens. Susan Collins (R., Maine) and Claire McCaskill (D., Mo.), chairman and ranking member of the